5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study

Clinical Colorectal Cancer

Volumn 4, Issue 5, 2005, Pages 325-331

  D'Andre, Stacy ^a   Sargent, Daniel J ^b   Cha, Stephen S ^b   Buroker, Thomas R ^c   Kugler, John W ^d   Goldberg, Richard M ^e   O'Connell, Michael J ^f   Poon, Michael A ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c Iowa Oncology Research Association Community Clinical Oncology Program   (United States)

^d Clinical Oncology Program   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

^g SASKATCHEWAN CANCER AGENCY   (Canada)

Author keywords

Age; Clinical trial; Drug toxicity; Pooled analysis; Survival; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ETHINYLURACIL; FLUOROURACIL; FOLINIC ACID; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PROGNOSIS; SCORING SYSTEM; STOMATITIS;

EID: 14644429819     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.005     Document Type: Article

References (37)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Jessup JM, McGinnis LS. Steele GD, Jr, et al. The National Cancer Data Base: report on colon cancer. Cancer 1996; 78:918-926.
3. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321:531-535.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
7. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
8. Sundararajan V, Grann VR, Neugut AI. Population based variation in the use of chemotherapy for colorectal cancer in the elderly. Proc Am Soc Clin Oncol 1999; 18:413a (Abstract #1598).
9. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J 2001; 7:213-218.
10. Grothey A, Buechele T, Feigl-Lurz S, et al. Survey-based analysis of treatment algorithms in colorectal cancer (CRC) in Germany discloses deficits in patient care. Proc Am Soc Clin Oncol 2000; 19:249a (Abstract #964).
11. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93:850-857.
12. Greenfield S, Blanco DM, Elashoff RM, et al. Patterns of care related to age of breast cancer patients. JAMA 1987; 257:2766-2770.
13. Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 1985; 33:585-589.
14. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74(suppl):2208-2214.
15. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067.
16. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21:1383-1389.
17. Petrelli N, Douglass HO, Jr, Herrera L, et al, for the Gastrointestinal Tumor Study Group: the modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7:1419-1426.
18. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer 1995; 75:11-17.
19. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-3541.
20. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulatiion of flourouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9:1967-1972.
21. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.
22. Goldberg RM, Hatfield AK, Kahn M, et al. A prospectively randomized North Central Cancer Treatment Group trial of intensive course 5-flourouracil combined with the 1-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 1997; 15:3320-3329.
23. Hobday TJ, Kugler JW, Mahoney MR, et al. Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol 2002; 20:4574-4580.
24. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherpy for colorectal cancer. J Clin Oncol 2002; 20:1491-1498.
25. Zalcberg J, Kerr D, Seymour L, et al, for the Tomudex‰ International Study Group. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer 1998; 34:1871-1875.
26. Chiara S, Nobile MT, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998; 42:336-340.
27. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17:2412-2418.
28. Mattioli R, Lippe P, Recchia F, et al. Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res 2001; 21:489-492.
29. Magne N, Francois E, Broisin L, et al. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am J Clin Oncol 2002; 25:126-130.
30. Berreta G, Bollina R, Cozzi C, et al, and Members of the GOAL-Group of Oncomedical Associates in Lombardy. Should we consider the weekly chemotherapy with fluorouracil and racemic folinic acid as standard treatment for advanced/metastatic carcinoma of the digestive tract in elderly patients? Proc Am Soc Clin Oncol 1997; 16:259a (Abstract #920).
31. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15:1330-1338.
32. Lévi F, Zidani R, Focan C, et al. Age-independent benefit of chronotherapy with 5-fluorouracil, leucovorin and oxaliplatin in patients with metastatic colorectal cancer within multicenter randomized phase III trials. Proc Am Soc Clin Oncol 2002; 21:358a (Abstract #1431).
33. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10:1171-1175.
34. Hall KE, Wiley JW. Age-associated changes in gastrointestinal function. In: Hazzard WR, Blass JP, Etinger WH Jr, et al, eds. Principles of geriatric medicine and gerontology. 4th ed. New York: McGraw-Hill, 1999:835-842.
35. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13:192-198.
36. Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9:449-452.
37. Clarke SJ, Abdi E, Davis ID, et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial. Proc Am Soc Clin Oncol 2001; 20:383a (Abstract #1529).